DNA: Ginkgo Bioworks Stock Price, Analysis & Forecast: 1 Year and 5 Year Targets
Ginkgo Bioworks: 1-Year and 5-Year Forecast Outlook and Rating
Ginkgo Bioworks (DNA) has an immediate Do Not Add consensus AI recommendation, based on 11 AI analysts.
The 1-year target is $7.79 for , with +4.42% expected return (+4.42% including net dividends) and a NEUTRAL rating.
The 5-year target is $7.44 for , with -0.27% expected return (-0.27% including net dividends) and a PARTIAL SELL rating.
Returns and dividends calculation details
Latest available market price: USD 7.46, as of 20 Nov 2026.
Calculated net annual dividend yield: 0%. As of 2026-11-20.
Gross TTM: 0% · Two-year annualized gross: 0%.
Tax withholding assumption: 30% (US). One-off special payments are excluded.
Original published assumption: 0% per year.
Return estimates compound the net annual yield at a constant rate over the stated return horizon (the remaining time to the fixed target date for current returns): (1 + price return) × (1 + net annual yield)years − 1.
Targets retain their original publication dates. Returns use the dated market close and the time remaining to each fixed target date. Current ratings also require fresh quotes and analysis, with more than 90 days remaining. Past targets have no forward return. Eligibility checked .
Ginkgo Bioworks Flagship Insight
Autonomous Lab Validation Meets The Financing Gap That Could Dilute Success

High consensus centers on a credible laboratory automation pivot constrained by cash consumption, legacy leases and equity dilution. Pharmaceutical reference wins improve survival prospects, but deployment delays and unproven recurring revenue limit shareholder value capture. Recast revenue and service-cost accounting complicate headline growth and margin comparisons.
How were the Investment Thesis and Forecasts created?
11 AI advisors, guided by 9 analytical frameworks, contribute to the deep analysis by iPulse AI Engine.
Michael Burry (Vulture)
Warren Buffett (Value Purist)
J.P. Morgan (Titan)
Machiavelli (Insider)
Universal Investor (Polymath)
Elon Musk (Visionary)
Superintelligence (Anthropologist)
Ray Dalio (Strategist)
Sherlock Holmes (Whistleblower)
Ran across these frontier AI models
Google Gemini 4 Hydrogen
OpenAI GPT-6.1 Sol
Anthropic Claude Opus 5.5
Ginkgo Bioworks: Investment Thesis Summary
If you invest $10,000 in Ginkgo Bioworks at the latest market close (20 Nov 2026): $9,973 by Nov 2031 versus $14,502 for S&P 500 benchmark.
Returns use the same dated market close, fixed targets and remaining dividend period as the forecast table.
Ginkgo Bioworks can build a useful laboratory automation franchise without delivering attractive economics to existing shareholders. Restructuring lowers the cash breakeven threshold, while pharmaceutical equipment wins and public laboratory deployments validate demand. Yet installation working capital, legacy occupancy commitments and continuing losses leave financing ahead of self-funding. Valuation therefore depends on recurring contribution profit and diluted ownership, not biology's productivity gains. The strongest counterargument is that repeat deployments and committed data purchases could simultaneously accelerate utilization and reduce equity issuance. However, reported gross margins exclude some service-delivery costs classified within research spending, and contract catch-ups obscure recurring demand; neither commercial scalability nor software economics is established.
Key insights
- Customer-funded installations can improve capital efficiency while worsening near-term cash conversion if inventory and acceptance milestones precede collections, increasing dilution before scale.
- Lease relief creates value through lower future cash outflows; deducting liabilities again after modeling rent can exaggerate downside and distort comparable valuation.
- Automation savings do not guarantee supplier rents: discounted assays may transfer productivity gains to customers unless repeat purchasing establishes durable pricing power.
Continue reading Ginkgo Bioworks analysis with Base subscription
See Base accessGinkgo Bioworks: 5 Year Consensus Forecast
20 quarterly price targets, returns and rationale, with advisor range and benchmark
Forward returns are updated using the latest market close price of USD 7.46, as of 20 Nov 2026.
Dividend calculation details
Calculated net annual dividend yield: 0%. As of 2026-11-20.
Gross TTM: 0% · Two-year annualized gross: 0%.
Tax withholding assumption: 30% (US). One-off special payments are excluded.
Original published assumption: 0% per year.
Return estimates compound the net annual yield at a constant rate over the stated return horizon (the remaining time to the fixed target date for current returns): (1 + price return) × (1 + net annual yield)years − 1.
The consensus target follows an expert-weighted price path synthesized from 11 AI advisor opinions. See Opinion weights and rationale for the exact allocation and reasoning.
Forecast methodology and reference values
Published targets are anchored on 13 Nov 2026 at USD 9.61. Original quarter-to-quarter target changes are retained. Forward returns use the remaining time to each fixed target date.
The pessimistic and optimistic advisor base cases are the lowest and highest published advisor base-case targets for each quarter. The advisor at either extreme can change between quarters. Benchmark values are in USD.
Scroll the table horizontally to read every column.
| Quarter | Consensus target (USD) | Forecast quarter-to-quarter price change | Forward price return | Forward return incl. net dividends | Forecast rationale | Pessimistic Advisor Base Case (USD) | Optimistic Advisor Base Case (USD) | S&P 500 benchmark (USD) |
|---|---|---|---|---|---|---|---|---|
| $8.78 | -8.62% | +17.69% | +17.69% | Anticipation of annual disclosures shifts attention from partnership announcements toward recurring receipts and financing needs. Elevated discount rates reinforce skepticism, while the contract catch-up makes recent sequential growth an unreliable foundation for extrapolating commercial momentum. | $8.48 | $9.05 | $736 | |
| $8.08 | -7.95% | +8.31% | +8.31% | Annual disclosures and early operating results test whether expense reductions are preserving liquidity fast enough. Continuing cash requirements and potential issuance outweigh initial deployment progress, even after correcting exaggerated revenue declines caused by discontinued-operation comparisons. | $7.80 | $8.59 | $724 | |
| $8.09 | +0.02% | +8.45% | +8.45% | Projected installation milestones and repeat pharmaceutical workflows provide a counterweight to legacy contraction. The balance remains finely poised because hardware recognition can improve reported revenue before recurring software contribution or dependable cash conversion becomes visible. | $7.25 | $8.64 | $722 | |
| $7.79 | -3.70% | +4.42% | +4.42% | Customer additions increasingly face scrutiny over contract size and repeatability. Under the favored scenario, uneven equipment revenue and persistent occupancy costs outweigh reference-site enthusiasm, highlighting the difference between technical adoption and revenue sufficient for self-funding. | $6.75 | $8.22 | $724 | |
| $7.25 | -6.86% | -2.82% | -2.82% | A smaller unrestricted treasury brings financing into sharper focus as the deployment cycle continues consuming resources. Orderly issuance can protect enterprise survival while reducing existing ownership, limiting the valuation benefit from a leaner operating structure. | $6.21 | $7.89 | $735 | |
| $7.01 | -3.33% | -6.03% | -6.03% | Renewals and broader assay usage support operating improvement, but financing supply remains the stronger influence across the weighted paths. Investors distinguish narrower adjusted losses from the cash needed to manufacture, install and support additional systems. | $5.28 | $8.27 | $752 | |
| $6.81 | -2.89% | -8.71% | -8.71% | Equipment working capital and uneven acceptance milestones expose the gap between accounting progress and available cash. Growing data workflows offer support, but cannot yet reliably offset issuance pressure, competitive procurement and the inherited real-estate burden. | $4.85 | $8.03 | $754 | |
| $6.88 | +1.01% | -7.77% | -7.77% | Projected commissioning progress and additional equipment references improve confidence that the platform can generate repeat business. Milestone collections and a broader installed base provide modest relief, although persistent financing needs prevent treating deployment growth as self-sustaining. | $4.56 | $8.34 | $780 | |
| $6.63 | -3.52% | -11.13% | -11.13% | Annual results expose the remaining distance between a larger installed base and dependable cash returns. Uneven acceptance, slow occupancy relief and residual funding requirements temper enthusiasm, despite more credible commercial activity than during the initial pivot. | $4.33 | $8.43 | $802 | |
| $6.85 | +3.26% | -8.18% | -8.18% | Repeat customers broaden their workflows and attached support becomes more economically visible. Better utilization and sales efficiency support renewed confidence in contribution profit, while the favorable interpretation remains conditional on collections rather than reported backlog alone. | $4.32 | $8.93 | $819 | |
| $6.72 | -1.84% | -9.92% | -9.92% | Renewed financing requirements can absorb the benefit of improving revenue and narrower losses. The central tension is ownership arithmetic: commercial growth strengthens the franchise, but additional shares reduce how much of that progress existing investors retain. | $4.45 | $9.21 | $821 | |
| $6.78 | +0.83% | -9.12% | -9.12% | Follow-on equipment work and support contracts make revenue less dependent on winning new customers every quarter. That gradual improvement supports stabilization, although unresolved facility costs and competitive pricing keep the recovery measured rather than a platform-style rerating. | $4.42 | $9.84 | $842 | |
| $6.77 | -0.13% | -9.25% | -9.25% | A more established commercial franchise meets continued variability in public ordering and facility expenses. Improving software and service activity broadly offsets cautious funding assumptions, leaving investors focused on whether operating progress can finally translate into durable cash. | $4.33 | $10.34 | $863 | |
| $6.97 | +2.93% | -6.57% | -6.57% | Repeat experimental services and support activity improve utilization without proportionate staffing growth. Modest occupancy relief in several paths adds operating leverage, supporting recovery while avoiding the unsupported assumption that all automation revenue earns software-like margins. | $4.41 | $10.75 | $871 | |
| $6.87 | -1.48% | -7.91% | -7.91% | Competitive offerings and deployment working capital constrain the benefit of rising throughput. Some paths anticipate stronger utilization and subleasing, but the greater-weighted caution is that customer savings and renewed issuance limit value retained by existing shareholders. | $4.29 | $11.08 | $874 | |
| $7.02 | +2.28% | -5.90% | -5.90% | Higher throughput begins absorbing central engineering and facility expenses more effectively. Improving adjusted profitability reduces perceived financing urgency, although cash reinvestment and remaining occupancy obligations mean accounting breakeven cannot automatically be equated with full self-funding. | $4.20 | $11.63 | $896 | |
| $7.16 | +1.91% | -4.02% | -4.02% | A maturing installed fleet produces steadier maintenance, support and experimental-service demand. Greater confidence in franchise durability supports the shares, while accumulated dilution and unresolved differences over free-cash-flow breakeven restrain enthusiasm about the quality of recovery. | $4.24 | $12.10 | $912 | |
| $7.21 | +0.71% | -3.35% | -3.35% | Repeat orders narrow cash consumption and reduce immediate financing anxiety, but equipment reinvestment remains necessary. Improvement is tempered by lumpy customer budgets and earlier ownership dilution, making the recovery more dependent on collections than expanding valuation multiples. | $4.16 | $12.46 | $924 | |
| $7.29 | +1.15% | -2.28% | -2.28% | Broader workflows within established pharmaceutical accounts support incremental growth and more predictable gross profit dollars. Competing automation systems and normalized service-and-equipment economics cap pricing power, keeping the investment case grounded in execution rather than renewed thematic enthusiasm. | $4.24 | $12.83 | $939 | |
| $7.44 | +2.00% | -0.27% | -0.27% | The horizon closes with a more credible automation franchise and substantially improved operating discipline. The dominant limitation remains cumulative financing and cash depletion, so greater enterprise capability does not translate proportionately into value for the original shares. | $4.19 | $13.36 | $965 |
Show remaining 18 quartersCollapse to first 2 quarters
All 20 quarters are displayed in the table above.
Ginkgo Bioworks Stock Analysis & Scenarios Deep Dive
Ginkgo Bioworks: Did the investment thesis change since the last deep analysis in September 2026?
The financing-constrained survival thesis remains intact, but current filings materially change how revenue quality, commercial validation and valuation should be interpreted.
Changes in the underlying thesis, rather than the passage of time alone.
- The prior view treated contraction largely as deliberate pruning. Current disclosures show both genuine continuing-business weakness and a material contract catch-up, making recurring demand less secure than a restructuring-only explanation suggests.
- Commercial reference wins strengthen the pivot, while service-cost classification and consistent lease treatment undermine categorical software-margin or permanently commoditized valuation claims. Financing and dilution remain decisive, with a wider credible range of operating outcomes.
Ginkgo Bioworks: Alpha Gap & Repricing Catalysts
Market Narrative
What does the market currently expect? External signals describe opposing narratives, not a uniformly bullish market. Quoted analyst summaries remain skeptical of shrinking sales and cash consumption, while reported options activity and sharp headline-driven rallies suggest speculative enthusiasm for AI-enabled laboratory infrastructure. The issuer promotes that repositioning. The supplied sales valuation implies commercialization optionality, but neither media coverage nor repeated report references establish a dominant public expectation.
Alpha Gap
What is the biggest difference between market expectations and our AI forecasts? The crowd overestimates value in the speculative turnaround trade, rather than in uniformly bullish market expectations. The best-supported gap is between technical validation and value accruing to existing shares: deployments can expand the enterprise while working capital, occupancy costs and equity issuance absorb the benefit. That favors caution toward a commercialization premium unsupported by recurring cash receipts. The strongest challenge is customer-funded repeat ordering, which could improve utilization and financing simultaneously. Skeptical analyst commentary already recognizes substantial risk, limiting claims of a broadly overlooked mispricing.
Repricing Catalyst
What could make the market recognize and close that gap? Annual disclosures and early-2027 results, expected across February–May, should expose the relationship between continuing revenue, unrestricted liquidity and issuance. Weak recurring receipts despite improving adjusted losses would make the financing gap harder to dismiss and support downward reassessment of speculative value. Through 2027–2029, repeat installations, collections and binding multisite orders provide the counter-test; credible convergence requires cash evidence, not another customer announcement, and successful conversion could instead narrow the financing discount.
Ginkgo Bioworks: Sentiment and Timing
What do sentiment, volatility, and the market-recognition cycle suggest about the thesis timing?
- Greed and Fear Sentiment
- Mixed
- Volatility Regime
- High Erratic
- Convergence Cycle Position
- Reversal
Reports agree on erratic volatility but split between residual speculative enthusiasm and financing anxiety. Most describe a reversal from headline-driven excitement, while others see stabilization or growing recognition. That tension makes cash-conversion evidence more important than momentum for timing the thesis.
Macro Regime Fit
Does the current market environment support the thesis? The setup is mixed but net adverse. Elevated yields penalize distant cash flows and increase the dilution cost of financing losses, while cautious customer budgets can delay equipment acceptance. Domestic procurement and research onshoring provide offsets. Capital availability and deployment funding matter more here than general economic growth; easier monetary conditions alone would not establish profitable demand.
Advisor Disagreement
What do our AI Advisors disagree about most? The real disagreement is whether repeat equipment sales and data workflows reach sufficient contribution profit before financing materially expands the share base. Optimistic paths assume software attachment, lease relief and eventual self-funding; cautious paths allow useful technology but retain price competition and repeated issuance. Some apparent disagreement instead reflects unrecast versus continuing revenue, GAAP versus adjusted research spending, and inconsistent treatment of leases. The contract catch-up weakens evidence of recurring growth but does not establish a permanent normalized run rate. Disclosed collections, repeat-order economics and cash requirements would resolve more than additional prestigious customer names.
Ginkgo Bioworks: Critical Influencing Factors
Near-certain positive forcesTop Drivers & Tailwinds
Near-certain forces that support the investment thesis. These forces are treated as part of the base case (at least 75% probability of occurrence, as generation guidance). Impact columns are specific to this asset class.
Scroll to view all columns
| Driver / Tailwind | Category | Est. stock-price impact | Est. earnings impact | Why it matters |
|---|---|---|---|---|
| Cost reset buys commercial time | Operational Efficiency | +25% | +35% | Lower research, staffing and IT spending materially reduces the revenue needed to sustain operations. The restructuring has already narrowed adjusted losses, making continued expense discipline more credible than an immediate demand rebound. Savings preserve runway and reduce financing urgency, although further cuts become harder as the organization approaches essential engineering and service capacity. |
| The laboratory becomes the product | Innovation And Product | +25% | +30% | Selling modular automation converts existing technical capabilities into customer-site equipment revenue and subsequent support opportunities. The Novo Nordisk reference win supports incremental deployments over the horizon without requiring industry-wide standardization. Installation delays and undisclosed software attachment limit visibility, but an expanding installed base can increase revenue density and recurring gross profit dollars. |
| Public installations validate commercial capability | Competitive Positioning | +20% | +20% | Public laboratory deployments supply both equipment demand and integration references that financially cautious private buyers can evaluate. PNNL independently confirms Ginkgo's participation, strengthening evidence beyond issuer promotion. Existing procurement channels should support incremental activity, but award ceilings and program participation are not guaranteed collected revenue, and future appropriations remain conditional. |
| Paid workflows broaden laboratory utilization | Sector And Industry | +18% | +20% | Pharmaceutical assay customers and biological-data collaborations create additional uses for the installed automation base. Domestic sourcing preferences and demand for reproducible experimental data support incremental paid workflows, reducing dependence on rationalized legacy programs. The durable opportunity is better utilization, not assured monopoly economics; discounted pricing means some productivity benefits remain with customers. |
Near-certain negative forcesTop Frictions & Headwinds
Near-certain forces that could slow, cap, or damage the thesis. These forces are treated as part of the base case (at least 75% probability of occurrence, as generation guidance). Impact columns are specific to this asset class.
Scroll to view all columns
| Friction / Headwind | Category | Est. stock-price impact | Est. earnings impact | Why it matters |
|---|---|---|---|---|
| Cash deficits dilute existing ownership | Capital Allocation | -35% | -15% | Continuing operating deficits consume unrestricted reserves before the new product base can reliably fund itself. Existing ATM activity demonstrates an available financing mechanism, while further issuance reduces each current share's participation in recovery. The earnings drag arises from operating losses, not dilution itself. Financing timing and terms remain uncertain rather than an inevitable emergency. |
| Replacement revenue meets price competition | Competitive Positioning | -30% | -25% | New laboratory revenue must first replace rationalized programs and reduced agriculture work before creating net scale. A contract-modification catch-up complicates recent growth signals, while established vendors and internal laboratories constrain pricing. Recast comparisons temper the apparent decline but do not eliminate commercial weakness or the risk that customer savings exceed Ginkgo's retained contribution profit. |
| Empty space keeps charging rent | Operational Efficiency | -25% | -25% | Long-dated occupancy commitments preserve part of the old cost base after staffing and laboratory consolidation. Excess space continues absorbing cash while subleasing remains difficult, delaying the benefit of higher utilization elsewhere. These are recognized lease obligations, not undisclosed borrowing; valuation must capture future rent consistently rather than subtracting the same burden twice. |
| Capital costs penalize delayed cash | Macroeconomic And Macrofinancial | -18% | -8.0% | Elevated discount rates reduce what investors pay for cash flows several years away, while constrained research budgets can extend equipment procurement cycles. This exposure persists while the company depends on outside capital, even if yields eventually normalize. Monetary easing could improve financing conditions, but it would not remove execution risk or establish recurring customer economics. |
Ginkgo Bioworks: What Could Break or Accelerate the Thesis
Event Risk Score: Very High 94/100Asset-level relative pressure from clustered consensus frictions and tail risks. This is not the probability or risk score of an individual force.Plausible downside scenariosTail Risks
Tail yet plausible downside scenarios selected for their highest potential impact.
Scroll to view all columns
| Tail scenario | Chance of Occurring | Stock Price Impact | Why plausible / what changes |
|---|---|---|---|
| Runway ends in punitive recapitalization | 40% | -60% | Weak bookings and sustained cash consumption during 2027–2029 could force a discounted placement with warrants or preferential financing terms. Unlike orderly issuance already embedded in the base case, this event would transfer substantially more value from existing holders and reinforce selling pressure. Remaining liquidity and demonstrated cost flexibility keep a financing crisis uncertain rather than inevitable. |
| Public deployments lose committed funding | 25% | -45% | Actual cancellation or material defunding of multiple government-supported laboratory deployments during 2027–2030 would remove revenue and valuable reference installations simultaneously. Conditional annual funding provides a concrete transmission channel, unlike unsupported predictions about particular political outcomes. Lost validation could also weaken private conversion and prolong cash consumption, although existing institutional commitments and strategic interest limit the event's probability. |
Plausible upside scenariosTail Opportunities
Tail yet plausible upside scenarios selected for their highest potential impact.
Scroll to view all columns
| Tail scenario | Chance of Occurring | Stock Price Impact | Why plausible / what changes |
|---|---|---|---|
| A pharma pilot becomes a fleet | 35% | +90% | A binding multisite pharmaceutical deployment agreement during 2027–2029 would turn a reference installation into evidence of repeatable procurement. Standardized builds, customer deposits and attached support could increase revenue while reducing financing needs. The probability remains below even odds because integration complexity, competing architectures and undisclosed deployment economics prevent extrapolating one major sale into enterprise-wide adoption. |
| An AI buyer reserves capacity | 25% | +110% | A frontier-model developer or pharmaceutical consortium could sign a take-or-pay experimental-data agreement during 2027–2030, with substantial minimum purchasing commitments. Reserved capacity would improve utilization, cash visibility and bargaining power together. Existing collaborations establish a channel, not this outcome; uncertain model economics, flexible purchasing preferences and internal robotics alternatives keep the probability limited. |
Company Financial AnalysisGinkgo Bioworks: Earnings and Financials Analysis by AI
Financial figures available as of Nov 16, 2026. Only filings and source records available by this analysis date are included. View latest Ginkgo Bioworks financials here.
Earnings and financials
Ginkgo's Q3 2026 SEC disclosures describe a smaller business with shrinking losses, not yet a demonstrated growth recovery. Continuing revenue of $27.7 million benefited from a $15.0 million contract-modification catch-up. Reduced agriculture work and rationalized programs weakened underlying demand, while the Biosecurity divestiture makes unrecast historical comparisons misleading. Staffing and IT cuts genuinely reduced expenses, but cash generation remains negative. The catch-up is recognized contract revenue, not evidence of wrongdoing; equally, it should not be treated as repeat sales. Subtracting it highlights timing dependence rather than establishing a dependable future run rate. Autonomous-laboratory collections must now prove that commercial progress can replace lost legacy activity.
Revenue, earnings, and cash flow
The table compares up to five fiscal years of revenue, net income, and free cash flow available to this analysis.
| Fiscal year | Revenue | Net income | Free cash flow |
|---|---|---|---|
| 2025 | USD 170.2M | USD -312.8M | USD -178.7M |
| 2024 | USD 227M | USD -547M | USD -382.1M |
| 2023 | USD 251.5M | USD -892.9M | USD -336.3M |
| 2022 | USD 477.7M | USD -2.1B | USD -304.5M |
| 2021 | USD 313.8M | USD -1.8B | USD -310.3M |
Valuation context: historical P/E
The table compares up to five fiscal years of point-in-time valuation evidence available to this analysis.
| Fiscal year | P/E | Earnings basis | Currency basis | Ticker / reporting |
|---|---|---|---|---|
| 2025 | -- | TTM | Loss-making | USD / USD |
| 2024 | -- | TTM | Loss-making | USD / USD |
| 2023 | -- | TTM | Loss-making | USD / USD |
| 2022 | -- | Annual | Loss-making | USD / USD |
| 2021 | -- | Annual | Loss-making | USD / USD |
P/E uses historical market capitalization and earnings known at each period. Cross-currency observations are normalized to USD using point-in-time FX rates.
Profitability and margins
The supplied FY2025 gross margin of 81.5% looks impressive beside an operating margin of negative 185%. The filings explain an important reason: some cell-engineering service costs are classified in research spending rather than direct revenue costs. The headline gross margin therefore does not establish software-like economics or independently prove attractive delivery margins. Restructuring has genuinely narrowed losses, but the company still needs collected revenue to cover engineering, facilities and corporate expenses. Hardware sales may lower the reported gross-margin percentage even while improving total profit dollars. Conversely, discounted assays can benefit customers without leaving Ginkgo enough profit. Sustained improvement requires recurring work to grow faster than the full cost of providing it.
The table compares up to five fiscal years of operating income and reported profitability margins.
| Fiscal year | Operating income | Operating margin | Net margin |
|---|---|---|---|
| 2025 | USD -315.3M | -185.3% | -183.8% |
| 2024 | USD -559.8M | -246.5% | -240.9% |
| 2023 | USD -864.4M | -343.8% | -355.1% |
| 2022 | USD -2.2B | -462.4% | -440.6% |
| 2021 | USD -1.8B | -582.6% | -583.1% |
Balance sheet and leverage
The September 2026 filings report $285.4 million in unrestricted cash and marketable securities, with no conventional bank debt. That provides breathing room rather than a cash floor shareholders can assume will remain intact. Continuing losses consume reserves, restricted collateral is not freely spendable, and the Biosecurity sale delivered an investment interest rather than cash proceeds. The same reporting shows $397.2 million in non-current operating lease liabilities. These recognized obligations fall due over years, but still restrict flexibility as unused space consumes cash. They should not be deducted again if valuation already includes future rent payments. Further equity financing is a plausible scenario, not an existing obligation or inevitable emergency.
The table compares up to five fiscal years of debt, liquidity, net cash or debt, and current-ratio evidence.
| Fiscal year | Total debt | Cash + short-term investments | Reported net cash / (debt) | Debt less (cash + short-term investments), calculated | Current ratio |
|---|---|---|---|---|---|
| 2025 | USD 439.9M | USD 422.6M | USD 272.7M net debt | USD 17.3M | 4.92x |
| 2024 | USD 467.7M | USD 561.6M | USD 93.8M net cash | USD -93.8M | 5.62x |
| 2023 | USD 239.3M | USD 944.1M | USD 704.8M net cash | USD -704.8M | 6.11x |
| 2022 | USD 442.6M | USD 1.3B | USD 873.2M net cash | USD -873.2M | 8.38x |
| 2021 | USD 23M | USD 1.6B | USD 1.5B net cash | USD -1.5B | 12.79x |
Reported net debt retains the source definition, which can deduct cash alone. Cash plus short-term investments is broader liquidity; the separately calculated column subtracts that full amount from total debt for the same fiscal period and currency. Reported net debt below zero is displayed as net cash. Current ratio is current assets divided by current liabilities.
Capex and investment intensity
The supplied FY2025 figures show capital spending falling to 4.5% of revenue from 27.5% in FY2024. Management's shareholder letter describes using the existing autonomous laboratory platform while selling similar equipment externally. This is a shift away from expanding Ginkgo's own footprint, not proof that laboratory automation has become an asset-light business. Lower construction spending conserves cash, but engineering remains an operating expense and old facilities still require payments. Customer-funded installations can improve capital efficiency, yet Ginkgo may need inventory and installation cash before collecting. The key investment question is whether existing assets generate repeat paid work. Restraint buys time; returns on the pivot remain unproven.
The table compares up to five fiscal years of capital expenditure and research-and-development investment.
| Fiscal year | Capital expenditure | R&D spend |
|---|---|---|
| 2025 | USD 7.7M | USD 243.8M |
| 2024 | USD 62.5M | USD 424.1M |
| 2023 | USD 40.8M | USD 580.6M |
| 2022 | USD 52.3M | USD 1.1B |
| 2021 | USD 56.5M | USD 1.1B |
Behind the synthesisGinkgo Bioworks: How Each Individual AI Forecaster Opinion Shapes the Global Consensus
This publication’s recorded synthesis allocated voting influence across 11 advisor opinions. The weights and rationales below are retained from that synthesis.
The strongest supported pattern is a genuine cost reset and credible automation validation that have not yet produced self-funding operations. Company filings establish liquidity and continuing losses; independent procurement evidence strengthens the case that the hardware has practical demand. Repeated partnership announcements, yield assumptions and lease figures largely share sources rather than provide independent confirmation. The strongest contrarian case is that repeat installations and committed data purchases improve utilization while reducing financing needs, allowing operating progress to reach existing shareholders. That possibility survives, but software-like margins and rapid breakeven remain unproven. Greater weight goes to analyses correcting reporting perimeters, service-cost classification and lease double-counting. Lower weights reflect unsupported political specificity, normalized-revenue claims derived from one quarter, speculative investigations and deterministic financing shocks. The resulting scenario favors enterprise survival with continuing dilution risk, not inevitable insolvency or an assured platform rerating.
Individual targets retain their original dates. Returns and ratings use the same latest available market close and dividend assumptions as the Consensus.
All 11 opinions
Consensus weight Allocation: 28.0/100. Weight Allocation Rationale: The highest weight rewards filing-based corrections to continuing revenue, service-cost classification and lease double-counting, plus independent procurement evidence. Its valuation explicitly connects enterprise growth, cash depletion and diluted ownership without denying technological utility. Terminal revenue and financing remain scenario assumptions, but the economic treatment is more internally consistent than competing paths.
The 1-year target is $7.84 for , with +5.15% expected return and a NEUTRAL rating. The 5-year target is $7.31 for , with -2.00% expected return and a PARTIAL SELL rating.
Consensus weight Allocation: 15.0/100. Weight Allocation Rationale: Specific filing receipts, recognition timing and separation of cash burn from equity proceeds strengthen the commercialization-to-financing bridge. The path reasonably allows both operational improvement and shareholder dilution. Weight is limited by potentially inconsistent lease-adjusted valuation, uncertain terminal reconciliation and unsupported attribution of stock movements to unrelated AI-company leadership events.
The 1-year target is $8.16 for , with +9.33% expected return and a BUY rating. The 5-year target is $8.10 for , with +8.55% expected return and a PARTIAL SELL rating.
Consensus weight Allocation: 10.0/100. Weight Allocation Rationale: The distinction between enterprise survival and shareholder compounding is economically persuasive, and installation delays connect coherently to financing requirements. Its evidence substantially overlaps other reports, however. Lease-adjusted valuation risks inconsistent treatment of occupancy costs, while specific political and monetary assumptions receive less evidentiary support than the operating-financing mechanism.
The 1-year target is $8.21 for , with +10.07% expected return and a BUY rating. The 5-year target is $7.98 for , with +6.94% expected return and a PARTIAL SELL rating.
Consensus weight Allocation: 8.0/100. Weight Allocation Rationale: The supported insight is that experimental data demand and lower overhead preserve meaningful commercialization optionality. However, the sustained late-horizon appreciation assumes recurring software economics, lease relief and profitability that existing orders do not establish. Shared company announcements provide limited independent confirmation, warranting a moderate weight rather than adopting the optimistic terminal trajectory.
The 1-year target is $8.01 for , with +7.41% expected return and a NEUTRAL rating. The 5-year target is $13.36 for , with +79.04% expected return and a BUY rating.
Consensus weight Allocation: 8.0/100. Weight Allocation Rationale: Reported liquidity, restructuring and commercial reference wins support the financing-constrained recovery scenario. The path nevertheless embeds a pronounced capital-raising drawdown without demonstrating its necessity or terms. Claims equating high reported gross margins with underlying unit economics overlook cost classification, and repeated sources do not independently validate the projected financing severity.
The 1-year target is $7.34 for , with -1.57% expected return and a PARTIAL SELL rating. The 5-year target is $6.67 for , with -10.65% expected return and a PARTIAL SELL rating.
Consensus weight Allocation: 8.0/100. Weight Allocation Rationale: The contract-modification catch-up is a material earnings-quality observation that survives scrutiny and deserves inclusion. Subtracting it does not establish a sustainable organic revenue run rate, however. Speculative investigation scenarios, unsupported liquidity-covenant language and a persistently declining terminal path reduce weight relative to the stronger filing-based accounting and financing analysis.
The 1-year target is $6.96 for , with -6.75% expected return and a SELL ALL rating. The 5-year target is $4.57 for , with -38.71% expected return and a SELL ALL rating.
Consensus weight Allocation: 7.0/100. Weight Allocation Rationale: The focus on cash generation, competitive distribution and diluted ownership provides a coherent challenge to partnership-driven enthusiasm. Its main evidence is highly correlated with the batch, while terminal valuation compression and share expansion remain assumptions. Gross-margin interpretation and comparisons spanning discontinued operations require corrections before accepting the full downside path.
The 1-year target is $8.22 for , with +10.19% expected return and a BUY rating. The 5-year target is $5.79 for , with -22.42% expected return and a SELL ALL rating.
Consensus weight Allocation: 6.0/100. Weight Allocation Rationale: The excess-space burden and potential value of lease settlements are useful, causally grounded insights. Lower weight reflects an unusually severe assumed financing episode, mixed historical revenue perimeters and reliance on speculative external AI-financing developments. The restructuring evidence supports continued cash pressure more clearly than the precise distressed-financing trajectory.
The 1-year target is $7.03 for , with -5.72% expected return and a SELL ALL rating. The 5-year target is $5.31 for , with -28.81% expected return and a SELL ALL rating.
Consensus weight Allocation: 5.0/100. Weight Allocation Rationale: Public procurement and governance can materially affect who captures the platform's value, and that distinctive connection merits retention. However, quantified sovereign option value, rigid annual dilution assumptions and legislative timing are insufficiently demonstrated. Government announcements overlap other reports and do not establish protected margins, guaranteed appropriations or an enduring valuation premium.
The 1-year target is $8.21 for , with +10.07% expected return and a BUY rating. The 5-year target is $8.62 for , with +15.58% expected return and a NEUTRAL rating.
Consensus weight Allocation: 4.0/100. Weight Allocation Rationale: The sequencing insight is valuable: viable automation can still require financing before deployments generate recurring cash. Lower weight reflects confident assumptions about installation timing, software attachment, later cash breakeven and customer economics. Technical demonstrations establish capability, not commercial scalability, and largely repeated announcements provide little independent support for the modeled recovery.
The 1-year target is $6.80 for , with -8.83% expected return and a SELL ALL rating. The 5-year target is $8.83 for , with +18.32% expected return and a NEUTRAL rating.
Consensus weight Allocation: 1.0/100. Weight Allocation Rationale: Minimal weight reflects absent source receipts, historical perimeter mismatches and continuing surveillance-revenue assumptions inconsistent with the documented Biosecurity divestiture. The warning about negative cash generation remains relevant, but neither the commercial support nor the severe terminal trajectory is adequately grounded. Those limitations substantially outweigh its overlap with better-supported financing concerns.
The 1-year target is $6.73 for , with -9.73% expected return and a SELL ALL rating. The 5-year target is $4.19 for , with -43.77% expected return and a SELL ALL rating.
References & Context
Research Provenance
Analysis generated by iPulse AI Engine v9 using recorded market data, operating under the editorial standards and supervision of Russlan Ramdowar, Editor-in-Chief.
External references below are sources recorded by the researcher agents for this Ginkgo Bioworks forecast batch.
Primary analysis inputs
- iPulse AI Multi-Agent Forecasts — independent analyst personas, model outputs, and consensus synthesis.
- iPulse AI Global Events Context — macroeconomic, geopolitical, regulatory, and industry-event context.
- Structured market history — prices, distributions, volatility, identifiers, and listing metadata.
- Company earnings and financial statements — revenue, profitability, balance-sheet, cash-flow, and investment trends.
- Researcher web evidence — public sources consulted to challenge and contextualize the forecast thesis.
Sources retained from AI Researcher searches
Asset-specific · Researcher web40 available sources from this batch (87 recorded). The first 15 are shown below; expand to read the rest.
Some model providers retained only the consulted domain, not an exact article URL. Those domains are shown as evidence without inventing a link.
- sec.gov sec.gov
- Test Bed: Toward a Network of Programmable Cloud Laboratories (PCL Test Bed) | NSF - U.S. National Science Foundation nsf.gov
- PNNL Breaks Ground on First-of-Its-Kind Autonomous Laboratory for Biosciences | News Release | PNNL pnnl.gov
- **We call this technology the autonomous lab.** sec.gov
- dna-20260403 sec.gov
- dna-20260630 sec.gov
- dna-20260930 sec.gov
- dna-20260930 sec.gov
- Ginkgo Bioworks Holdings, Inc. - Form 10-Q - FY2026 sec.gov
- Ginkgo Bioworks Holdings, Inc. - Form 8-K - FY2026 sec.gov
- Ginkgo Bioworks Holdings, Inc. - Form 8-K - FY2026 sec.gov
- https://www.sec.gov/Archives/edgar/data/1830214/000162828026068220/q32026announcement.htm?utm_source=openai sec.gov
- www.sec.gov sec.gov
- www.sec.gov sec.gov
- senate.gov senate.gov
Show 25 more sources
- stocktitan.net stocktitan.net
- tradingview.com tradingview.com
- ginkgobioworks.com ginkgobioworks.com
- seekingalpha.com seekingalpha.com
- tickeron.com tickeron.com
- gurufocus.com gurufocus.com
- marketbeat.com marketbeat.com
- tradingkey.com tradingkey.com
- biospace.com biospace.com
- q4cdn.com q4cdn.com
- businesswire.com businesswire.com
- fool.com fool.com
- jimmyresearch.com jimmyresearch.com
- koalagains.com koalagains.com
- quantisnow.com quantisnow.com
- biopharmawatch.com biopharmawatch.com
- lighthorse.io lighthorse.io
- morningstar.com morningstar.com
- perplexity.ai perplexity.ai
- prnewswire.com prnewswire.com
- stockanalysis.com stockanalysis.com
- tipranks.com tipranks.com
- biorxiv.org biorxiv.org
- finsee.ai finsee.ai
- finviz.com finviz.com
47 additional sources are recorded in this batch; their citation details are not available in this publication.
Context retained with this Consensus
The same public-safe market, global-event, and fundamental context supplied to the AI Advisor panel.
Global context snapshot
2026 Year-to-Date Global Market and World-Events Context Through November 14
Download Archived SnapshotCoverage 2026-01-01 to 2026-11-14 · Knowledge cutoff 2026-11-14
January 1-November 14, 2026: persistent inflation, partial oil supply recovery, US midterms and trade, AI financing, and uneven growth.
Archived context covering 2026-01-01 to 2026-11-14. Its recorded scope includes monetary policy and rates; geopolitics energy and shipping; trade and industrial policy. Selected highlights reflect the analysis cutoff, not current world conditions.
Show moreShow less
- File size
- 96K bytes
- Words
- 14.2K words
- Characters
- 96K characters
- Est. tokens (characters ÷ 4)
- 24K tokens
Fed held at 3.75%-4.00%; Democrats won the next Congress, Nvidia changed leadership and Anthropic filed preliminary IPO terms. Markets through November 13.
| Selected highlights from this archived snapshot | Date | Status |
|---|---|---|
| Renewed monetary tightening amid persistent inflation | 2026-01-30 | ACTIVE POLICY REGIME |
| Iran/Hormuz conflict and wider energy-security disruption | 2026-02-28 | ONGOING |
| US tariff reset, trade truce and incoming divided government | 2026-02-20 | ACTIVE POLICY REGIME |
Representative Sources of the Context File
And more sources from the retained context package.
Fundamental Context Passed as Input to the Models
Time range: Annual fiscal periods: 2019-12-31–2025-12-31, 7 periods; Quarterly fiscal periods: 2023-12-31–2026-09-30, 12 periods.
Currencies cited: USD (quote USD; primary reporting USD; converted/valuation USD).
Show moreShow less
Income statement
9 fieldsdepreciationAndAmortization · ebit · ebitda · grossProfit · +5 more fields
Balance sheet
11 fieldscash · commonStockSharesOutstanding · netDebt · netReceivables · +7 more fields
Cash flow
5 fieldscapitalExpenditures · dividendsPaid · freeCashFlow · salePurchaseOfStock · +1 more field
End of the paywalled preview
The excerpt from Deep Dive: detailed analysis to this notice is the simplified paywalled content included on this page. A signed-in, verified account with the required subscription provides the full interactive interface and the additional research, datasets and tools listed below.
Those additional materials are not included in this preview and cannot be revealed by removing its visual restrictions.
Additional with full access
Individual AI Advisor reports
- Investment theses
- Bull and bear scenarios and alpha signals
- Drivers, headwinds, risks and opportunities
- Quarterly forecast rationale
- Advisor research references and configuration
Additional datasets and interactive tools
- Interactive forecast comparisons
- Available detailed financial statements
- Market history and corporate-action adjustments
- Eligible historical publication workspaces
Explore complete public research examples
These public assets show the complete AI Consensus research. Their findings concern those assets, not this report.
Ginkgo Bioworks: forecast questions
What is Ginkgo Bioworks (DNA)'s 1-year price forecast?
Ginkgo Bioworks's 1-year target is $7.79 for Nov 2027. The current AI rating is NEUTRAL. The expected return from the recorded close is +4.42%, or +4.42% modeled return including net dividends. Latest available market price: USD 7.46, as of 20 Nov 2026. The target date is fixed at publication.
What is Ginkgo Bioworks (DNA)'s 5-year price forecast?
Ginkgo Bioworks's 5-year target is $7.44 for Nov 2031. The current AI rating is PARTIAL SELL. The expected return from the recorded close is -0.27%, or -0.27% modeled return including net dividends. Latest available market price: USD 7.46, as of 20 Nov 2026. The target date is fixed at publication.
How can I compare the AI opinions and audit past Ginkgo Bioworks forecasts?
11 AI analysts contribute to this publication. AI Opinions shows individual advisor forecasts and reasoning. Forecast History lists the available batches with their original publication dates.
How does an AI-generated forecast for Ginkgo Bioworks differ from Wall Street analyst consensus?
Wall Street consensus aggregates estimates from human analysts. For listed companies, these typically include brokerage price targets, earnings forecasts and ratings. iPulse AI's forecast for Ginkgo Bioworks is a separate AI consensus generated through its own research workflow. Different inputs, forecast dates, assumptions and weighting can therefore produce different targets.
We believe the era of investment research conducted only by human analysts is drawing to a close. Frontier models increasingly match or exceed expert work on selected professional benchmarks, including evaluations covering financial analysis. Research on multi-model synthesis also shows that combining model responses can improve on a single model's output in the tasks studied.
iPulse AI generates transparent investment research and market forecasts using a swarm of AI configurations, analytical frameworks and frontier models. The workflow applies multiple verification, challenge and synthesis layers, with selective editorial review under Russlan Ramdowar, Editor-in-Chief. Published assumptions, disagreements and past forecasts remain available so readers can inspect the reasoning and audit outcomes.
For a research cycle covering 426 assets with 14 perspectives per asset, our internal workload model estimates approximately 114,000 hours of traditional analyst work. It assumes 16 hours per individual research report, 28 hours per consensus for synthesis and validation, plus shared data preparation. Parallel AI execution allows a deep-analysis cycle across hundreds of assets to complete in up to one day. The human-hours figure is an illustrative workload estimate, rather than measured time savings. Our research methodology explains the automated workflow.
If iPulse AI produces thousands of investment reports - work estimated to require over 100,000 traditional analyst hours - isn't that just "AI slop" at scale?
No. iPulse AI produces AI-generated research at scale, but the purpose is depth of analysis, comparison, and accountability. The number of reports is a consequence of the research process; it is not the goal.
iPulse AI does not produce thin copies of existing websites, articles, or investment reports. We use frontier models as an Analytical Intelligence layer. Our Financial Experts select, validate, curate, and supply the input data, including proprietary inputs, so the models work from a prepared evidence base.
In Researcher mode, models can also search the web to check current information, test assumptions, and investigate evidence that may be missing from the supplied data. This can include lobbying expenditure, management developments, regulatory decisions, or other facts relevant to a particular investment thesis. Thinker mode focuses on deep reasoning over the supplied data and context.
Our process goes much further than asking ChatGPT to evaluate a stock. Our team designs structured investment frameworks inspired by the approaches of influential investors, economists, political thinkers, and technological visionaries. These are AI analytical frameworks, not reports written or endorsed by the people who inspired them.
Each asset is analyzed separately through multiple frameworks and configurations, using specialized inputs and task instructions. Different perspectives examine different questions: valuation, business quality, technological disruption, macroeconomic conditions, political influence, financial risks, and more.
Cloud infrastructure allows these workflows to run at scale. That scale also comes with quality assurance at scale: up to 30% of report-generation attempts fail our QA checks. We rerun failed attempts until a clean report passes those checks. Users are presented only with reports that have passed QA.
This explains the volume. The value comes from what we do with the analysis.
A second layer synthesizes the individual reports into an asset-level consensus. This is where we recommend starting when researching a particular asset: it brings together the central thesis, supporting evidence, risks, and disagreements while preserving access to the underlying opinions.
We then compare assets through our proprietary iPulse AI Consensus Score, whose methodology is publicly explained. This helps users move from understanding one asset to comparing opportunities across the analyzed universe.
A further research and editorial layer examines leading candidates, checks current evidence, and develops focused Editorial Top Picks across broad-market and dedicated asset categories. Human editors review the evidence and approve each published edition. For example, explore our Best Long-Term Investments.
But the process does not end when a report is published. We preserve past forecasts so users with the relevant subscription can inspect what the system actually said and compare it with subsequent market outcomes. As more forecasts reach their target dates, the historical record becomes more useful for evaluating which approaches worked, which failed, and under what conditions.
We publish research on our website, arXiv, and Zenodo, alongside explanatory writing on Medium. We use the evidence to refine our data, frameworks, validation, and workflows, and document important findings in Lessons Learned.
The standard we ask users to judge us by is the reasoning, evidence, and historical record behind the research.
How does the iPulse AI Engine work?
The engine runs AI advisor configurations against a shared set of research inputs. The engine history explains the research workflow and what changed between versions.








